EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19

While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO trial –  on Siltuximab (Sylvant©). EUSA has published the following Press Release on the subject – and preliminary results could be found here – .

Under this Emergency Access Program, EUSA Pharma will make Siltuximab (Sylvant®) available in response to unsolicited requests by healthcare providers on an individual named-patient basis in accordance with local and international regulations.

About Sylvant®

SYLVANT® is a monoclonal antibody that blocks the action of interleukin-6 (IL-6), a multifunctional cytokine detected at elevated levels in iMCD patients.

Program Contact details

All requests must be submitted by the treating physician on behalf of the patient. Healthcare providers can obtain details about the Siltuximab Emergency Access Program by contacting FarmaMondo’s dedicated email address

About FarmaMondo

FarmaMondo is a Swiss-headquartered pharmaceutical group focused on providing market access and specialty distribution services, through a unique infrastructure and geographical footprint targeted to providing access to medicines across unlicensed and licensed phases.

For more information about FarmaMondo please visit

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies, and is supported by significant funding raised from leading life science investor EW Healthcare Partners.

For more information about EUSA Pharma please visit